TaiMed Biologics (ROCO:4147) Beneish M-Score: -3.10 (As of Jul. 11, 2026)


ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$69.50
GF Value NT$85.90
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics Beneish M-Score?

TaiMed Biologics ROCO:4147 55 Beneish M-Score is -3.10 as of Jul. 11, 2026. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.90 (Modestly Undervalued). Among 823 Biotechnology companies, TaiMed Biologics ranks better than 78.01% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.1 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for TaiMed Biologics's Beneish M-Score or its related term are showing as below:

ROCO:4147' s Beneish M-Score Range Over the Past 10 Years
Min: -3.1   Med: -2.27   Max: 15.02
Current: -3.1

During the past 13 years, the highest Beneish M-Score of TaiMed Biologics was 15.02. The lowest was -3.10. And the median was -2.27.


TaiMed Biologics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics Beneish M-Score Chart

TaiMed Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.73 -2.61 -2.23 -2.27 -3.10

TaiMed Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.27 -2.64 -2.80 -2.41 -3.10

ROCO:4147 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, TaiMed Biologics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiMed Biologics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's Beneish M-Score falls into.


ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of TaiMed Biologics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8964+0.528 * 0.8157+0.404 * 0.9459+0.892 * 1.0019+0.115 * 0.9541
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.958+4.679 * -0.074608-0.327 * 1.1859
=-3.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$96.1 Mil.
Revenue was 149.897 + 147.672 + 137.54 + 176.241 = NT$611.4 Mil.
Gross Profit was 43.334 + 57.401 + 67.447 + 91.269 = NT$259.5 Mil.
Total Current Assets was NT$3,322.3 Mil.
Total Assets was NT$4,810.7 Mil.
Property, Plant and Equipment(Net PPE) was NT$807.4 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$153.6 Mil.
Selling, General, & Admin. Expense(SGA) was NT$72.3 Mil.
Total Current Liabilities was NT$253.5 Mil.
Long-Term Debt & Capital Lease Obligation was NT$463.0 Mil.
Net Income was -68.538 + -13.985 + -59.451 + -25.802 = NT$-167.8 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.0 Mil.
Cash Flow from Operations was 25.952 + 115.293 + 4.137 + 45.762 = NT$191.1 Mil.
Total Receivables was NT$107.0 Mil.
Revenue was 145.766 + 138.508 + 146.94 + 178.948 = NT$610.2 Mil.
Gross Profit was 9.708 + 75.387 + 57.933 + 68.197 = NT$211.2 Mil.
Total Current Assets was NT$3,393.7 Mil.
Total Assets was NT$4,999.2 Mil.
Property, Plant and Equipment(Net PPE) was NT$857.4 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$154.3 Mil.
Selling, General, & Admin. Expense(SGA) was NT$75.3 Mil.
Total Current Liabilities was NT$134.8 Mil.
Long-Term Debt & Capital Lease Obligation was NT$493.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(96.098 / 611.35) / (106.993 / 610.162)
=0.15719 / 0.175352
=0.8964

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(211.225 / 610.162) / (259.451 / 611.35)
=0.346179 / 0.42439
=0.8157

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3322.308 + 807.385) / 4810.741) / (1 - (3393.658 + 857.402) / 4999.247)
=0.141568 / 0.14966
=0.9459

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=611.35 / 610.162
=1.0019

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(154.283 / (154.283 + 857.402)) / (153.61 / (153.61 + 807.385))
=0.152501 / 0.159845
=0.9541

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(72.256 / 611.35) / (75.277 / 610.162)
=0.118191 / 0.123372
=0.958

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((462.999 + 253.507) / 4810.741) / ((493.122 + 134.765) / 4999.247)
=0.148939 / 0.125596
=1.1859

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-167.776 - 0 - 191.144) / 4810.741
=-0.074608

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

TaiMed Biologics has a M-score of -3.10 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.10 mean?
TaiMed Biologics (ROCO:4147) has a Beneish M-Score of -3.10 as of Jul. 11, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on TaiMed Biologics and its competitors. According to the industry distribution chart, TaiMed Biologics ranks #181 out of 823 companies in the Biotechnology industry, placing it in the top 22%.
Is TaiMed Biologics' Beneish M-Score too high?
TaiMed Biologics' current Beneish M-Score is -3.10. Based on the distribution chart, TaiMed Biologics ranks #181 out of 823 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #181 out of 823 companies for Beneish M-Score. This places TaiMed Biologics in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current Beneish M-Score is -3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current Beneish M-Score is -3.10. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Beneish M-Score is -3.10 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • Beneish M-Score: -3.10
  • GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.50
Price
NT$85.90
GF Value